Kuteesa Job
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kuteesa Job has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Frank Asiimwe
Mulago National Referral Hospital
4 shared publications - Badru Ssekitooleko
Makerere University
3 shared publications - Bashir Ssuna
Department of Obstetrics and Gynecology, Makerere University College of Health Sciences, Kampala, Uganda
3 shared publications - D Namuguzi
College of Health Sciences, Makerere University
3 shared publications - Haruna Muwonge
Department of Physiology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda
3 shared publications - Hawa Nalwoga
College of Health Sciences, Makerere University
3 shared publications
Latest Publications
- 1 August 2025
- Published by Medpharm Publications in African Urology
- Vol. 5 (3) , 89-93
Expression patterns of EGFR, PD-L1, and Ki-67 among Ugandan patients with muscle-invasive bladder cancer
- 1 August 2025
- Published by Medpharm Publications in African Urology
- Vol. 5 (3) , 89-93
Expression patterns of EGFR, PD-L1, and Ki-67 among Ugandan patients with muscle-invasive bladder cancer
- 1 March 2025
- Published by Medpharm Publications in African Urology
- Vol. 5 (1) , 5-9
Unravelling bladder cancer in Uganda: insights from the discrepancies in TP53 assessment between immunohistochemistry and whole exome sequencing
- 1 March 2025
- Published by Medpharm Publications in African Urology
- Vol. 5 (1) , 5-9
Unravelling bladder cancer in Uganda: insights from the discrepancies in TP53 assessment between immunohistochemistry and whole exome sequencing
- Open Access
- 1 March 2024
- Published by Medpharm Publications in African Urology
- Vol. 4 (1) , 1-6
A histopathological study of bladder cancer in Uganda
Background: The incidence of squamous cell carcinoma (SCC) and adenocarcinoma of the bladder have been higher than that of urothelial carcinoma (UC) in several African countries for nearly five decades. However, this trend has changed over time, with ...
- 1 March 2024
- Published by Medpharm Publications in African Urology
- Vol. 4 (1) , 1-6
Open AccessA histopathological study of bladder cancer in Uganda
Background: The incidence of squamous cell carcinoma (SCC) and adenocarcinoma of the bladder have been higher than that of urothelial carcinoma (UC) in several African countries for nearly five decades. However, this trend has changed over time, with ...
- Open Access
- 14 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (12) , 2544-2550
Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry
Prostate cancer risk is influenced by rare and common germline variants. We examined the aggregate association of rare germline pathogenic/likely pathogenic/deleterious (P/LP/D) variants in ATM, BRCA2, PALB2, and NBN with a polygenic risk score (PRS) on prostate cancer risk among 1,796 prostate cancer cases (222 metastatic) and 1,424 controls of African ancestry. Relative to P/LP/D non-carriers at average genetic risk (33%–66% of PRS), men with low (0%–33%) and high (66%–100%) PRS had Odds Ratios (ORs) for overall prostate cancer of 2.08 [95% confidence interval (CI) = 0.58–7.49] and 18.06 (95% CI = 4.24–76.84) among P/LP/D carriers and 0.57 (95% CI = 0.46–0.71) and 3.02 (95% CI = 2.53–3.60) among non-carriers, respectively. The OR for metastatic prostate cancer was 2.73 (95% CI = 0.24–30.54) and 28.99 (95% CI = 4.39–191.43) among P/LP/D carriers and 0.54 (95% CI = 0.31–0.95) and 3.22 (95% CI = 2.20–4.73) among non-carriers, for men with low and high PRS, respectively. Lifetime absolute risks of overall prostate cancer increased with PRS (low to high) from 9.8% to 51.5% in P/LP/D carriers and 5.5% to 23.9% in non-carriers. Lifetime absolute risks of metastatic prostate cancer increased with PRS from 1.9% to 18.1% in P/LP/D carriers and 0.3% to 2.2% in non-carriers These findings suggest that assessment of prostate cancer risk for rare variant carriers should include PRS status. Significance: These findings highlight the importance of considering rare and common variants to comprehensively assess prostate cancer risk in men of African ancestry.
- 14 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (12) , 2544-2550
Open AccessPolygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry
Prostate cancer risk is influenced by rare and common germline variants. We examined the aggregate association of rare germline pathogenic/likely pathogenic/deleterious (P/LP/D) variants in ATM, BRCA2, PALB2, and NBN with a polygenic risk score (PRS) on prostate cancer risk among 1,796 prostate cancer cases (222 metastatic) and 1,424 controls of African ancestry. Relative to P/LP/D non-carriers at average genetic risk (33%–66% of PRS), men with low (0%–33%) and high (66%–100%) PRS had Odds Ratios (ORs) for overall prostate cancer of 2.08 [95% confidence interval (CI) = 0.58–7.49] and 18.06 (95% CI = 4.24–76.84) among P/LP/D carriers and 0.57 (95% CI = 0.46–0.71) and 3.02 (95% CI = 2.53–3.60) among non-carriers, respectively. The OR for metastatic prostate cancer was 2.73 (95% CI = 0.24–30.54) and 28.99 (95% CI = 4.39–191.43) among P/LP/D carriers and 0.54 (95% CI = 0.31–0.95) and 3.22 (95% CI = 2.20–4.73) among non-carriers, for men with low and high PRS, respectively. Lifetime absolute risks of overall prostate cancer increased with PRS (low to high) from 9.8% to 51.5% in P/LP/D carriers and 5.5% to 23.9% in non-carriers. Lifetime absolute risks of metastatic prostate cancer increased with PRS from 1.9% to 18.1% in P/LP/D carriers and 0.3% to 2.2% in non-carriers These findings suggest that assessment of prostate cancer risk for rare variant carriers should include PRS status. Significance: These findings highlight the importance of considering rare and common variants to comprehensively assess prostate cancer risk in men of African ancestry.